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Abstract
In 2009, basic care packages (BCP) containing health products were distributed to HIV-infected persons in Ethiopia who
were clients of antiretroviral therapy clinics. To measure health impact, we enrolled clients from an intervention hospital and
comparison hospital, and then conducted a baseline survey, and 7 bi-weekly home visits. We enrolled 405 intervention
group clients and 344 comparison clients. Intervention clients were more likely than comparison clients to have detectable
chlorine in stored water (40% vs. 1%, p,0.001), soap (51% vs. 36%, p,0.001), and a BCP water container (65% vs. 0%, p,
0.001) at every home visit. Intervention clients were less likely than comparison clients to report illness (44% vs. 67%, p,
0.001) or health facility visits for illness (74% vs. 95%, p,0.001), and had lower median illness scores (1.0 vs. 3.0, p,0.05).
Participation in the BCP program appeared to improve reported health outcomes.
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Introduction
Diarrhea and other opportunistic infections are important
causes of morbidity and mortality among people living with HIV/
AIDS (PLHIV) [1–5]. Inexpensive interventions to prevent
opportunistic infections in resource-poor settings can improve
clinical outcomes in PLHIV [5–11] and may help reduce viral
loads and maintain CD4+ cell counts (CD4 counts) [12–15].
Consequently, the US President’s Emergency Plan for AIDS
Relief (PEPFAR) now authorizes use of program funds to procure
and distribute proven health interventions (e.g., insecticide treated
bednets, condoms, household water treatment products, soap) as
part of HIV care and support programs [16].
Among the interventions shown to reduce the risk of diarrhea in
PLHIV is household water treatment using a locally produced
sodium hypochlorite solution and safe water storage using a
narrow-mouth container with tap [5,7]. In Ethiopia, two water
treatment products for home chlorination are available: sodium
hypochlorite solution with the brand name Wuha Agar, which is
marketed at a price of USD 0.24 for a bottle that treats 1,000 liters
of water, and a flocculent-disinfectant product with the brand
name PuR that clarifies and disinfects water [17], and is available
in Ethiopia at a price of USD 0.06 for a sachet that treats 10 liters.
In June 2009, with PEPFAR funding provided though the
United States Agency for International Development (USAID)
program, the Ministry of Health of Ethiopia and Population
Services International (PSI) began a program to distribute basic
preventive care packages (BCPs) [18,19] to HIV-infected persons
receiving antiretroviral therapy (ART). The BCPs were distributed
through a phased roll-out to clinics in five regions of Ethiopia:
Tigray, Amhara, Oromia, Southern Nations, Nationalities and
Peoples (SNNP), and Addis Ababa. Each BCP included: 6 bottles
of Wuha Agar (enough to treat 20 liters of water/day for 6
months), 24 sachets of PuR (enough to treat 10 liters of water/day
for 24 days), a 20 L jerrican with a lid and tap for safe water
storage, 100 condoms, 4 bars of soap, 4 doses of albendazole
(enough for one dose per quarter), and a low literacy illustrated
information booklet in Amharic promoting appropriate water
treatment, sanitation and hygiene practices. Cotrimoxazole
prophylaxis was provided free to clients at ART clinics when
indicated, as per Ethiopian Federal Ministry of Health guidelines
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[20]. Distribution of the BCP to clients was accompanied by
demonstration of product use by trained hospital staff. All products
contained in the BCP, except for the water storage container, were
available on the market in Ethiopia before the BCP program
began.
During the last quarter of 2009, 75,000 BCPs were distributed,
with another 125,000 BCPs distributed in 2010 and 2011. The
expense and effort to implement this program warrants an
evaluation of impact. From September 2009 through January
2010, we assessed the use, acceptability, and health impact of the
BCP on ART clients in Amhara, the region with the highest
proportion of patients receiving ART in Ethiopia as a consequence
of its large population size, and the high adult HIV prevalence
rates (approximately 4.5%: 3.2% in rural and 13.5% in urban
settings) [21,22].
Materials and Methods
Study Population and Sample Size Calculations
Using previously published methods [5,7] we conducted a
longitudinal evaluation of the BCP program among PLHIV
(hereafter referred to as clients) enrolled in ART programs.
Because of resource constraints, this evaluation was limited to a
convenience sample of two health facilities in Amhara Region,
Ethiopia. We selected the health facilities based on similar
numbers of clients currently receiving ART, demographic
characteristics, estimated risk for diarrheal disease, and, for
logistical reasons, ease of access by road. The Amhara Regional
Health Bureau designated Gonder University Hospital, a large
teaching hospital under the administration of the Department of
Education that provides treatment for 3,175 ART clients, as the
intervention site and Debre Markos Zonal Hospital, a large
regional hospital under the auspices of the Ethiopian Ministry of
Health that provides treatment for 2,056 ART clients, as the
comparison site. The ART programs in both of these facilities
were supported by International Training & Education Center for
Health (ITEC, Seattle, Washington). Even though Gonder
Hospital is an academic hospital, the HIV clinics at both hospitals
are run by ITEC as the PEPFAR contracted partner organization.
The two sites were similar in terms of clinical oversight, located in
a town, access to the health facility (all participants lived within
10 km of the health facility), geography, climate, and ethnic group
representation (.95% of participants at both sites were of Amhara
ethnicity). Both communities are at altitudes .2,000 m (i.e. not at
high risk of malaria transmission [Gonder 2,133 m; Debre Markos
2,446 m]) and have similar climates.
A sample size of approximately 400 persons each in the
intervention and comparison groups was estimated to detect a
10% reduction in illnesses in the intervention group relative to the
comparison group, with 80% power, 95% confidence, and a 25%
drop out rate. We limited participation to one client per
household.
Adult clients ($18 years old) enrolled in the HIV care and
treatment program and receiving ART treatment who lived within
a 10 km radius of the selected health facilities were eligible for
inclusion. Because records lacked sufficient information to locate
patients and daily patient load was relatively low, random selection
of participants was not feasible. Clients who consented to
participate were consecutively enrolled during clinic visits until
the target sample size was reached or the eligible client population
was exhausted.
Baseline Survey
Field workers administered a baseline questionnaire in Amharic
from September 24–October 23, 2009 to participants at both
health facilities to gather information about demographic and
socioeconomic characteristics; water, sanitation and hygiene
knowledge and practices; and utilization rates of BCP components.
Clinic nurses at both health facilities also abstracted medical
information from clients’ hospital charts including the most
recently recorded CD4 count, functional status, prescription of
cotrimoxazole prophylaxis, and duration of ART. Intervention
group clients received the BCP after completion of the baseline
questionnaire. Fieldworkers accompanied clients to their homes
after the baseline interview to make observations on water
treatment, storage, and hygiene and sanitation facilities, and to
test stored drinking water for free residual chlorine using the N, N-
diethyl-p-phenylenediamine (DPD) colorimetric method (LaMotte
Co., Baltimore, MD) as an objective measure of water treatment.
Biweekly Home Visits
Following the baseline survey, field teams began biweekly home
visits to study participants from both groups on October 8, 2010 to
ask about water, sanitation and hygiene practices; ongoing use of
BCP components and cotrimoxazole prophylaxis; illnesses in the
48 hours preceding the visit; health facility visits or hospitalizations
in the previous 14 days; and perceived BCP-associated stigma
among clients in the intervention group. Fieldworkers tested stored
drinking water for free residual chlorine and made observations of
BCP components and cotrimoxazole tablets in the home. Deaths
among study participants were also recorded. Biweekly home visits
continued for seven rounds. Comparison group clients received
the BCP at the end of the study, in January 2010.
Definitions and Statistical Analysis
We defined diarrhea as $3 loose or watery stools in a 24 hour
period; respiratory infection as reported fever and $2 of the
following signs and symptoms: cough, difficulty breathing, or
respiratory rate .20 breaths per minute; and febrile illness as
reported subjective fever without concurrent signs and symptoms
of diarrhea or respiratory illness. Additionally, we calculated a
total illness score for each client that summed all illnesses reported
for the previous 48 hours at each home visit and all reported
health facility visits or hospitalizations for any illness. Illnesses
spanning multiple home visits were counted each time they were
reported.
Data were double-entered in Ethiopia into EPI Info (CDC,
Atlanta, GA, USA). Data analysis was performed using SAS
version 9.2 (SAS Institute, Cary, NC, USA). Product use and
illness data between groups were compared using Chi-Square tests
for categorical variables. We performed categorical data analysis
on continuous variables based on natural breakpoints within the
data and compared differences between the two groups using Chi-
Square tests. The total illness score was weighted to account for
severity of illness, with self-reported health facility visits for illness
or hospitalizations contributing double the value of self-reported
acute illnesses in the previous 48 hours for which clients did not
seek care. Additional weighting factors for health facility visits and
hospitalizations were also evaluated, with no impact on outcomes,
therefore the most conservative weighting factors were chosen.
Health facility visits for HIV follow-up care (e.g., ART refills,
blood testing for CD4 counts) were not included in the total illness
score. Because total illness scores were not normally distributed,
we used the Wilcoxon rank-sum test to test for statistical
significance. Estimation of correlation structures within individuals
over time and across all measured variables was not appropriate in
Preventive Interventions among PLHIV
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this study due to the lack of stability in such estimates that can arise
from the relatively small sample size, weak correlation, and highly
skewed distributions. In collapsing the data over time, we lost
power, but gained simplicity and robustness. We choose to present
a common analysis for all variables that facilitates comparisons,
although for some variables the data were sufficient to incorporate
correlation structures in the analysis; the scientific findings were
not altered by this approach.
Ethical Review
The study protocol was approved by an Institutional Review
Board of the Centers for Disease Control and Prevention, Atlanta,
GA, USA (Protocol Number 5543), and the Ethiopian Public
Health Association (Protocol Number IERC 0030). Written
informed consent was obtained at the beginning of the study
from all participants.
Results
We enrolled 405 clients in the intervention group and 344
clients in the comparison group. Overall, 26 (0.3%) clients refused
to participate. We excluded from analysis 29 (7%) intervention
group clients and 36 (10%) comparison group clients who did not
complete all rounds of biweekly surveillance, including 8 who died
(3 in the intervention and 5 in the comparison group). The
reported cause of death as per the medical chart in the
intervention group clients was suicide (1), pneumonia (1), unknown
cause (1), and in the control group was car accident (1), chronic
liver disease and pulmonary tuberculosis (1), diarrhea/vomiting
(2), pulmonary tuberculosis and pneumonia (1).
Baseline Survey
The mean age of study participants was 36 years (range 19–69
years); 75% were female (Table 1). Over a third of participants
had no formal schooling, and more than 65% earned no income.
Nearly 70% of clients lived in a rented home and over 80% lived
in households with 5 or fewer members. There were no significant
differences in demographic characteristics between intervention
and comparison group clients.
At baseline, more than 95% of clients in both groups were
assessed by ART clinical staff as able to work (Table 2). At the
time of enrollment, 81% of clients in the intervention group and
77% in the comparison group had been on ART for .12 months.
Based on abstracted medical records, .99% of clients in both
groups had good adherence to ART (,5% of doses missed). Most
recently recorded median CD4 counts were similar at baseline for
both intervention and comparison group clients (284 and 274
cells/mL, respectively). The range of CD4 counts in the
intervention and control groups respectively were 26% vs. 33%
,200 cells/mL, 38% vs. 35% 200–,350 cells/mL, 20% vs. 19%
350–.500 cells/mL, and 17% vs. 12% $500 cells/mL. A higher
percentage of clients in the comparison group than in the
intervention group were receiving cotrimoxazole prophylaxis
(79% vs. 68%, p,0.05) at baseline.
The main source of drinking water was either public or private
piped water for 98% of intervention group participants and 88%
of comparison group participants. All households stored drinking
water in the home. At baseline, 48% of clients reported that they
did not treat their drinking water. At baseline, before receiving the
BCP, 29% of intervention group clients reported currently treating
their drinking water with Wuha Agar compared to 13% of
comparison group clients (p,0.05); 20% of stored water samples
in the intervention group and 8% in the comparison group had
detectable free chlorine residuals (p,0.05); baseline differences
were likely a result of intermittent distributions of products in the
community by non-governmental organizations.
At baseline, similar percentages of clients in the intervention
and comparison groups reported having soap in the home (76%
vs. 78%). A significantly higher percentage of clients in the
intervention than in the comparison group reported presence of
PuR (21% vs. 0%, p,0.05), condoms (24% vs. 12%, p,0.05), and
albendazole tablets (16% vs. 2%, p,0.05) in the home, while
significantly fewer intervention group clients than comparison
group clients reported having Wuha Agar in the home (24% vs.
42%, p,0.05).
Biweekly Home Visits
Over seven rounds of home visits (16 weeks), a significantly
higher percentage of intervention group clients than comparison
clients were observed to have Wuha Agar (91% vs 19%, p,0.001),
PuR (73% vs 0%, p,0.001), condoms (60% vs 3%, p,0.001),
soap (51% vs 36%, p,0.001), albendazole (69% vs 0%, p.0.001),
and a BCP water storage container (65% vs 0%, p,0.001) in the
home at all visits (Table 3). A similar percentage of intervention
and comparison group clients had cotrimoxazole tablets in the
home at all visits (53% vs 57%).
During home visits, the percent of intervention group clients
reporting water treatment with Wuha Agar ranged from 71% to
82% and the percentage with free chlorine residuals detected in
drinking water ranged from 67% to 78% (Figure 1). In the
comparison group, neither reported Wuha Agar use, nor observed
free chlorine residuals exceeded 10% at any home visit. Observed
PuR in the home among the intervention group ranged from 83%
to 90% during the home visits, with a median count of 24 sachets
(range 3, 37) at all 7 home visits. Over 7 rounds of home visits, a
significantly higher percentage of intervention group clients than
comparison clients reported treating their water with Wuha Agar
(45% vs 2%, p,0.001) and were observed to have free residual
chlorine in stored water at all visits (40% vs 1%, p,0.001)
(Table 3).
A similar percentage of intervention and comparison group
clients reported during 50% or more of home visits that they had
purchased soap in the preceding 2 weeks (Table 3). More
comparison than intervention clients reported during at least
50% of home visits that they had purchased cotrimoxazole (18%
vs 4%, p,0.001) or received free cotrimoxazole (13% vs 2%, p,
0.001) in the preceding 2 weeks.
During the study, 75% of intervention group clients reported
they were concerned that their friends or neighbors might learn
they had received the BCP, which could signal their HIV status.
However, only 8% reported feeling discriminated against because
of the BCP, and 67% told friends or family about components of
the BCP that they had received.
Intervention group clients were less likely than comparison
clients to report illness from any cause (44% vs 67%, p,0.05) or at
least one episode of febrile illness (28% vs. 38%, p,0.05) in the 48
hours preceding home visits (Table 4). Over the 14 days preceding
home visits, intervention clients were less likely than comparison
clients to report health facility visits for any illness (74% vs. 95%,
p,0.05), respiratory illness (5% vs. 10%, p,0.05), or fever (9% vs.
15%, p,0.05). Intervention group clients reported fewer hospi-
talizations for any cause (1% vs. 3%, p = 0.12) and health facility
visits for diarrhea (4% vs. 7%, p = 0.11) than comparison clients,
but the differences were not statistically significant. The median
illness score was 1.0 (range 0, 22) for intervention group clients and
3.0 (range 0, 33) for comparison group clients (p,0.05, Table 5).
Preventive Interventions among PLHIV
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Table 1. Baseline demographic characteristics of study participants in intervention and comparison groups, basic care package
evaluation, Gonder and Debre Markos, Ethiopia, October 2009.
Characteristic
Intervention
Group (n = 376)
Comparison
Group (n = 308) p-value
Overall
(n = 684)
Mean age 6 SDa 35.669.5 37.0610.0 0.05 36.269.7
Age group, n (%)b 18–25 years 49 (12.1) 43 (12.5) 0.7 92 (12.3)
26–35 years 193 (47.7) 145 (42.2) 0.3 338 (45.1)
36–45 years 101 (24.9) 88 (25.6) 0.6 189 (25.2)
.45 years 62 (15.3) 68 (19.8) 0.06 130 (17.4)
Female, n (%)b 278 (73.9) 234 (75.9) 0.6 512 (74.9)
Ethnicity, n (%) Amharab 360 (95.7) 302 (98.1) 0.1 662 (96.8)
Tigrayc 10 (1.5) 2 (0.7) 0.08 12 (1.8)
Oromoc 2 (0.5) 3 (0.8) 0.7 5 (0.7)
No formal schooling, n (%)b 121 (32.2) 109 (35.4) 0.4 230 (33.6)
Do not earn income, n (%)b 254 (67.6) 200 (64.9) 0.5 454 (66.4)
Living in rented house, n (%)b 260 (69.2) 212 (68.8) 0.9 472 (69.0)
Number of persons living in household
in past six months, n (%)b
1 to 5 298 (79.3) 269 (87.3) ,0.05 567 (82.9)
.5 78 (20.7) 39 (12.7) ,0.05 117 (17.1)
Comparison between intervention and comparison groups using Kruskal-Wallis testa, Chi-Square testb, or Fisher exact testc.
doi:10.1371/journal.pone.0107662.t001
Table 2. Clinical characteristics and treatment of ART clients at baseline, by study group, basic care package evaluation, Gonder
and Debre Markos, Ethiopia, October 2009.
Characteristic
Intervention
Group (n = 376)
Comparison
Group (n = 308)
Functional status, n (%)
Ambulatory 11 (3.0) 13 (4.2)
Working 361(97.0) 295 (95.8)
CD4 count in cells/mL, median (range) 284 (3–996) 274 (31–1088)
Time on ART treatment in months, median (range) 28.5 (0.1–67.3) 24.6 (0.2–73.2)
.12 months on ART treatment, n (%) 304 (81.1) 238 (77.3)
Adherence to ART drugsa, n (%)
Good 372 (99.2) 306 (99.4)
Fair 3 (0.8) 1 (0.3)
Poor 0 1 (0.3)
Currently on cotrimoxazoleb, n (%) 256 (68.3) 243 (78.9)
Adherence to cotrimoxazolea, n (%)
Good 253 (98.8) 240 (98.8)
Fair 1 (0.3) 2 (0.6)
Poor 3 (0.8) 1 (0.3)
Client reported following conditions at visit, n (%)
Diarrhea 2 (0.5) 0
Coughinga 2 (0.5) 6 (2.0)
Tuberculosis positivec 47 (22.6) 27 (6.5)
aSelf reported adherence obtained from medical records defined as follows: good (,5% of doses missed); fair (5–15% of doses missed); poor (.15% of doses missed).
bSignificant difference observed between intervention and comparison groups at p,0.05 using Chi-square test.
cTuberculosis diagnosis and staging differed between the health care facilities; for this reason no further analysis of tuberculosis was conducted.
doi:10.1371/journal.pone.0107662.t002
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Discussion
Findings of this study, which was the first to attempt to ascertain
the health impact of a program to provide BCPs to PLHIV,
suggested that recipients of the BCP were likely to have a lower
illness score derived from self-reported illnesses, health facility
visits, and hospitalizations than PLHIV who did not receive the
BCP. Rates of reported diarrheal illness, and health facility visits or
hospitalizations for diarrhea among intervention clients were also
lower than in comparison clients, but disease rates were too low to
provide the power to conclude that the differences were
statistically significant. Nevertheless, the results are consistent with
evidence from five high-quality studies, including four randomized
controlled trials and one systematic review and meta-analysis
which support the beneficial impact of interventions to improve
household drinking water quality on the health of PLHIV and
their families [5,23–26].
The differences between the two groups in reported illness and
health facility visit rates occurred following documentation of
similar functional status, CD4 cell counts, duration on ART,
adherence to ART, and adherence to cotrimoxazole prophylactic
treatment among intervention and comparison clients at baseline,
and in spite of the finding that a lower percentage of intervention
clients than comparison clients were on cotrimoxazole prophylaxis
at baseline. Furthermore, a higher percentage of clients in the
comparison than the intervention group reported during home
visits that they had received free Wuha Agar, soap, condoms, and
cotrimoxazole from other health facility-based programs and had
bought cotrimoxazole, all of which would likely diminish the
differences in health outcomes between the two groups. Finally,
these findings were observed despite relatively low rates of illness,
which were likely a result of ART and cotrimoxazole prophylaxis
[5,6], and suggested that, even in a setting of low illness rates, the
BCP may provide incremental clinical benefits to patients
receiving these treatments. An alternative interpretation is that
differences between the two communities may have accounted for
the findings. Health findings were congruent with reported and
confirmed use of BCP components documented in this study.
Specifically, intervention clients were more likely than comparison
clients to be observed with BCP components in their homes,
including Wuha Agar, PuR, BCP water containers, condoms,
soap, and albendazole. Similarly, clients who received the BCP
were significantly more likely than comparison clients to report
treating their stored drinking water with Wuha Agar and have free
chlorine residuals in stored drinking water. By removing the
economic barriers to access to these products through free
distribution, [27–29] the program created an opportunity for
participants to use them, and participants took advantage of this
opportunity, as has been observed in at least one other evaluation
[17]. Without free distribution, it is likely that use of different BCP
components would have been lower in this population because
two-thirds earned no income.
Economic barriers to sustained use of the BCP components
could diminish or eliminate health gains observed in this study
Table 3. Percentage of clients observed to have interventions in the home; reported and observed water treatment behaviors;
and reported receipt of interventions, by intervention and comparison group, over 16 weeks of basic care package evaluation,





Group (n = 308) p-value
Interventions observed in home at every visit
Wuha Agar 341 (90.7) 59 (19.2) ,0.001a
PuR 276 (73.4) 0 (0.0) ,0.001a
Condoms 224 (59.6) 10 (3.3) ,0.001a
Soap 192 (51.0) 111 (36.0) ,0.001a
Cotrimoxazole 198 (52.7) 174 (56.5) 0.35
Albendazole 258 (68.6) 0 (0.0) ,0.001a
BCP container 243 (64.6) 0 (0.0) ,0.001a
Water treatment
Reported treating water at every visit 177 (47.1) 5 (1.6) ,0.00a
Reported treating water with Wuha Agar at every visit 170 (45.2) 5 (1.6) ,0.001a
Water tested positive for free chlorine residual at every visit 152 (40.4) 3 (1.0) ,0.001a
Reported buying water treatment products at $5% of visits 5 (1.4) 2 (5.0) 0.15
Received free Wuha Agar at $5% of visits 19 (5.1) 51 (16.6) ,0.001a
Reports of interventions purchased or received
Bought soap at $50% of visits 316 (84.0) 267 (86.7) 0.38
Bought soap at every visit 149 (39.6) 117 (38.0) 0.69
Received free soap at $10% of visits 26 (6.9) 35 (11.4) 0.04
Bought cotrimoxazole at $10% of visits 13 (3.5) 55 (17.9) ,0.001a
Received free cotrimoxazole at $50% of visits 6 (1.6) 39 (12.7) ,0.001a
Received free condoms at $15% of visits 3 (0.8) 16 (5.2) ,0.001a
Bought condoms at $10% of visits 20 (5.3) 12 (3.9) 0.47
aRemains significant at ,0.001 after controlling for False Discover Rate [38].
doi:10.1371/journal.pone.0107662.t003
Preventive Interventions among PLHIV
PLOS ONE | www.plosone.org 5 September 2014 | Volume 9 | Issue 9 | e107662
because only one BCP per client is provided and clients may not
be able or willing to replenish consumable commodities in the
BCP such as Wuha Agar, condoms, and albendazole. Research in
other settings has shown that repeated purchase of inexpensive
commodities in low income populations often does not take place,
[27–29] even following a free trial [27,30,31]. To our knowledge,
only one other evaluation, which took place in Uganda, has
examined use of BCP components among PLHIV, and this study
was conducted before depletion of the original supply of
intervention components [18]. An evaluation of use of BCP
components over time in both the Ethiopian and Ugandan
programs is warranted and could help guide programming. In
addition, an assessment of the costs and benefits of a program of
free resupply of BCP commodities would be useful for guiding
policy, [32,33] particularly in view of evidence that integration of
free health interventions into health services can serve as an
incentive to increase use of services [34].
Some of the components of the BCP distributed in Ethiopia
may be unnecessary. For example, soap was observed in a similar
percentage of homes in both evaluation groups throughout the
evaluation, and similar percentages of clients reported purchasing
soap, suggesting that the BCP did not likely change access to or use
of soap. In contrast, despite the baseline observation that a higher
percentage of intervention than comparison households had PuR
in the home, possibly as a result of previous distribution efforts by
local organizations, use of PuR in this evaluation appeared to be
low, as suggested by the observation that the median number of
PuR sachets in intervention client homes remained at 24, the total
number provided in the BCP, throughout the 7 rounds of home
visits. One possible explanation for this observation is that most
intervention clients had access to piped water, which tended to be
clear and not in need of flocculation, and access to Wuha Agar for
in-home chlorination. By eliminating items from the BCP that are
already present or infrequently used in most households, resources
could be more efficiently directed toward alternative interventions.
The finding that about half of clients in both groups had
cotrimoxazole in the home at every visit, and that relatively few
patients reported buying or receiving it for free, was of some
concern. Prophylactic treatment with cotrimoxazole has been
shown to reduce morbidity and mortality from opportunistic
infections among PLHIV [6], including those on ART and has
been recommended for inclusion in BCPs [35]. High adherence to
recommended prophylactic treatment has been achieved in other
programs [6,11] and assuring regular access and use of the drug
should be a priority.
This study had several important limitations. First, BCPs were
not randomly distributed because that would have caused
potentially disruptive, inequitable treatment of clients, logistical
complications for nursing staff, and ethical concerns. We therefore
chose to compare health outcomes in the context of a phased BCP
distribution to intervention and comparison sites that were chosen
on the basis of similar population characteristics. The resultant
quasi-experimental design with just two study sites was subject to
potential confounding factors, such as differences between the two
study sites in geography; climate; demographic and socio-
economic status; household water management habits; and health
Figure 1. Percent of clients with reported water treatment with Wuha Agar, free chlorine residual in stored water, and observed
BCP container, at baseline (before receiving the BCP) and by home visit round, by intervention and comparison group, basic care
package evaluation, Gonder and Debre Markos, Ethiopia, October–January, 2010.
doi:10.1371/journal.pone.0107662.g001
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care delivery practices. Thus, we cannot rule out that the findings
observed could have been due to differences between the two
communities. However, while health care delivery and water
treatment practices differed at baseline between the two groups,
the large magnitude of difference observed between the two
populations during the study would have been highly unlikely
without the relatively intensive intervention that took place.
Second, because of logistical and financial considerations, we were
limited to two sites in one region of Ethiopia, so the evaluation
population was neither representative of Amhara state nor the
country as a whole and, therefore, different results might be
observed in other populations. Donors providing major invest-
ments into interventions such as those described here should
budget adequately for an evaluation component to avoid similar
situations. Third, because all clients enrolled in the study lived
within a 10 km radius of the town, information about clients living
in more remote settings was unavailable. Fourth, biweekly home
visits may have influenced responses to questions and observable
Table 4. Percent of clients self-reporting one or more episodes of illness, health facility visit, and hospitalization by intervention




Group (n = 376)
Comparison
Group (n = 308) p-value
Illness in previous 48 hours 165 (43.9) 206 (66.9) ,0.001c
Diarrhea in previous 48 hours 37 (9.8) 39 (12.7) 0.27
Respiratory illness in previous 48 hours 53 (14.1) 50 (16.2) 0.55
Fever in previous 48 hours 105 (27.9) 117 (38.0) ,0.005c
Health facility visits in previous 14 days 277 (73.7) 292 (94.8) ,0.001c
Health facility visit for diarrhea in previous 14 days 14 (3.7) 20 (6.5) 0.11
Health facility visit for respiratory illness in previous 14 days 20 (5.3) 32 (10.4) 0.01c
Health facility visit for malaria in previous 14 days 5 (1.3) 3 (0.1) 0.74
Health facility visit for fever in previous 14 days 35 (9.3) 45 (14.6) 0.04
Health facility visit for STI in previous 14 days 3 (0.8) 1 (0.3) –
Health facility visit for HIV care in previous 14 daysb 30 (8.0) 67 (21.8) ,0.001c
Health facility visit for other illness in previous 14 days 93 (24.7) 111 (36.0) 0.001c
Hospitalization in previous 14 days 5 (1.3) 10 (3.3) 0.12
Hospitalization for diarrhea in previous 14 days 0 (0) 2 (0.7) 0.2
Hospitalization for respiratory illness in previous 14 days 0 (0) 1 (0.3) 0.45
Hospitalization for malaria in previous 14 days 0 (0) 0 (0) –
Hospitalization for fever in previous 14 days 0 (0) 2 (0.7) 0.2
Hospitalization for STI in previous 14 days 0 (0) 0 (0) –
Hospitalization for HIV care in previous 14 daysb 0 (0) 2 (0.7) 0.2
Hospitalization for other illness in previous 14 days 5 (1.3) 10 (3.3) 0.12
aIllnesses spanning multiple home visits were counted each time they were reported over 16 weeks of basic care package evaluation.
bHealth facility visits and hospitalizations for HIV care, including changes in ART medications, CD4 counts, etc. do not contribute towards the illness score.
cRemains significant at ,0.05 after controlling for False Discover Rate [38].
doi:10.1371/journal.pone.0107662.t004
Table 5. Total number of illnesses, health facility visits, and hospitalizations reported over 16 weeks of basic care package
evaluation, and illness scores derived from these events, by intervention and comparison group, Gonder and Debre Markos,












Illness in previous 48 hours 653 946 1 653 946
Health facility visits in
previous 14 days
220 310 2 440 620
Hospitalization in previous
14 days
5 15 2 10 30
Total illness score 1,103 1,596
Median illness score per
patient (range)
1.0 (0–22) 3.0 (0–33)
doi:10.1371/journal.pone.0107662.t005
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household practices, resulting in a Hawthorne effect [36], but this
effect would likely have impacted both the intervention and
comparison groups. Fifth, because the evaluation was designed to
evaluate the BCP as a whole we had limited ability to tease out the
effect of specific interventions in the package on specific diseases,
and could not elucidate which interventions in the package drove
the findings. Finally, because of resource limitations, active
surveillance was limited to 14 weeks; therefore we were not able
to follow clients until consumable BCP components were
exhausted, limiting our ability to determine whether their use
was sustained over time. In addition, the short duration of the
study made it difficult to assess whether illness patterns varied
seasonally and over time, or whether there was attrition in the
health impact of water treatment interventions over time, which
has been observed elsewhere [37].
Because of these limitations, the findings of this evaluation must
be interpreted with caution. However, results of this study suggest
that, taken as a whole, the BCP is a promising method of
increasing access to inexpensive interventions that can reduce the
risk of disease and improve the quality of life of PLHIV. This
evaluation also highlighted the importance of evaluating BCP
programs in order to assure maximum health impact and optimal
use of scarce resources.
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